Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (VERV 2.00%) big stock price leap this week. By the time the dust cleared, the biotech company's shares soared 40% higher over the period, according to data compiled by S&P Global Market Intelligence.
Verve is a clinical-stage biotech, so its success depends on how it's progressing with its pipeline. The indications were quite encouraging this week when the company published initial data from a phase 1b clinical trial of VERVE-102, a drug targeting heterozygous familial hypercholesterolemia (HeFH) -- a genetic disorder that causes high cholesterol levels -- and premature coronary artery disease.
In the trial involving 14 patents, the treatment appeared to be efficacious, particularly in reducing low-density lipoprotein cholesterol (LDL-C) levels in the body. It was also well tolerated with no serious adverse events reported.
Following the news, analysts tracking Verve stock wasted little time publishing bullish new notes on the stock. Several raised their price targets with one -- Cantor Fitzgerald -- even upgrading its recommendation to the equivalent of a buy.
Not every analyst was so hot on Verve in the wake of the readout; JPMorgan Chase pundit Eric Jospeh actually lowered his price target (to $16 per share from $19).
Generally, though, prognosticators greeted the development positively. BMO Capital's Kostas Biliouris, in reiterating his outperform (i.e, buy) recommendation, according to reports wrote in a fresh note that the drug's performance beat expectations, and its safety profile positioned it in "a wide therapeutic window."
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。